Company profile
Cardiol Therapeutics Inc.
NASDAQ: CRDL · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Oakville, ONCIK 0001702123Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 43DQ —GM —SS 47
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ filing timeliness, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$24.2M
Employees
18
as of 2026-08-14
Market cap
$197.1M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$24.2M-33.8M CAD2025
Total assets$17.2M23.6M CAD2025
Liabilities$4.2M5.7M CAD2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cardiol Therapeutics Inc.’s financial profile?
Cardiol Therapeutics Inc. earned -$24.2M in FY2025 net income.
Peers · Healthcare
AN2 Therapeutics, Inc.——Galectin Therapeutics Inc.——PepGen Inc.——Atrium Therapeutics, Inc.——Acumen Pharmaceuticals, Inc.——Organigram Global Inc.——Key facts
CEODavid G. Elsley
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersOakville, ON
ExchangeNASDAQ: CRDL
Employees18
IPO date2019-01-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.